- Home
- MTAK vs RXST Comparison
MTAK vs RXST Comparison
Compare MTAK & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MTAK | RXST |
|---|---|---|
| Founded | 2026 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.2M | 208.8M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MTAK | RXST |
|---|---|---|
| Price | $9.87 | $4.88 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $7.57 |
| AVG Volume (30 Days) | 31.8K | ★ 615.3K |
| Earning Date | N/A | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.36 |
| Revenue Next Year | N/A | $1.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.83 | $4.40 |
| 52 Week High | $9.93 | $13.22 |
Technical Indicators
Market Signals| Indicator | MTAK | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 45.95 | 47.00 |
| Support Level | N/A | $4.55 |
| Resistance Level | N/A | $4.98 |
| Average True Range (ATR) | 0.01 | 0.23 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 100.00 | 61.39 |
Price Performance
Historical ComparisonAbout MTAK Market Technology Acquisition Corp Class A Ordinary Shares
Market Technology Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar Business Combination with one or more businesses.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.